The long-term research objective of Project 1 is to correlate molecular changes in DNA and RNA with establishment, progression, and metastasis of colon cancer. We will use three technologies developed in our laboratory: Multiplexed Ligase Detection Reaction (LDR) assays, Universal DNA arrays, and EndoV/DNA ligase mutation scanning assay. These technologies will identify point mutations, deletions, LOH, gene copy number, methylation status, and gene expression level in dozens of oncogenes and tumor suppressor genes within individual colon tumors. By capturing these genetic and epigenetic changes in important genes, the molecular profiles will allow us to identify new patterns and mechanisms of cancer gene activation and repression. Further, we will identify the genetic changes most important for metastatic progression to specific secondary sites, and in concert with Projects 2 and 3 construct and validate a molecular prognostic scoring system based upon genes that independently influence prognosis.
Our specific aims are: (i), (ii) To identify important interactions between both known and putative oncogenes and tumor suppressor genes from (a) defined signaling pathways, and (b) candidate genes identified in adenocarcinomas and precursors by cDNA expression array analysis and prioritized in Project 2 and 3. Tumor sample (360 total), including aberrant crypts, adenomas, adenocarcinomas, liver and lung metastasis will be analyzed. We will use molecular changes in key genes from the p53, cell cycle, apoptosis, Wnt signaling, RPTK signaling, and TGFbeta signaling pathways as the foundation for interpreting how such changes provide a cell survival advantage, and contribute to progressive autonomous growth and metastasis of colon cancers. (iii) To ascertain which mutations or alterations in gene expression correlate with colon cancer metastasis, in (a) receptor protein kinases (RPTKs), their known ligands, and (b) candidate genes identified in liver and lung metastases and prioritized in Projects 2 and 3. We will identify the autocrine and paracrine activation loops mediated by specific RPTKs and their ligands in primary and metastatic tumors. (iv) To employ biostatistical and bioinformatic approaches (Project 3) to determine which alteration(s) identified in Projects 1 and 2, and Core B correlate with recurrence and survival. Two separate cohorts of resected Stage 2/3 primary colon cancers (400 total) with good and poor outcomes will be analyzed to identify and validate genes that independently influence prognosis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA065930-05A2
Application #
6683028
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-08-30
Project End
2006-06-30
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065
Khan, Sajid A; Zeng, Zhaoshi; Shia, Jinru et al. (2017) EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathol Oncol Res 23:673-677
Khan, Sajid A; Morris, Melinda; Idrees, Kamran et al. (2016) Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. J Pediatr Surg 51:1812-1817
Cheng, Yu-Wei; Pincas, Hanna; Huang, Jianmin et al. (2014) High incidence of LRAT promoter hypermethylation in colorectal cancer correlates with tumor stage. Med Oncol 31:254
Bacolod, Manny D; Barany, Francis (2011) Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 18:3694-700
Dharmasiri, Udara; Njoroge, Samuel K; Witek, Ma?gorzata A et al. (2011) High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal Chem 83:2301-9
Nash, Garrett M; Gimbel, Mark; Cohen, Alfred M et al. (2010) KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 17:416-24
Bacolod, Manny D; Barany, Francis (2010) Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 12:552-61
Cheng, Yu-Wei; Idrees, Kamran; Shattock, Richard et al. (2010) Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. Int J Cancer 127:568-77
Pingle, Maneesh; Rundell, Mark; Das, Sanchita et al. (2010) PCR/LDR/universal array platforms for the diagnosis of infectious disease. Methods Mol Biol 632:141-57
Nash, Garrett M; Gimbel, Mark; Shia, Jinru et al. (2010) KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17:572-8

Showing the most recent 10 out of 74 publications